Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
4 search results for:

Ixazomib 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 12-08-2017 | Multiple myeloma | Article

    Dose and schedule selection of the oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma: Clinical and model-based analyses

    This study showsweekly ixazomib 4 mg to have a favorable benefit–risk profile on days 1, 8, and 15 of 28-day cycles for the treatment of patients with multiple myeloma. Gupta N, Yang H, Hanley MJ et al. Targ Oncol 2017. doi:10.1007/s11523-017-0524-3

  2. 24-01-2017 | Multiple myeloma | Article

    Proteasome inhibitors in cancer therapy

    This review analyzes the latest advances and challenges resulting from the introduction of proteasome inhibitors into the clinical setting for patients with multiple myeloma. Nat Rev Clin Oncol 2017. doi:10.1038/nrclinonc.2016.206

    Author:
    Elisabet E. Manasanch, Robert Z. Orlowski
  3. 10-01-2017 | Multiple myeloma | Article

    Multiple myeloma in 2016: Fresh perspectives on treatment and moments of clarity

    A comprehensive overview of the latest updates in 2016 and a prospective look towards the therapeutic landscape in 2017 for patients with multiple myeloma.  Nat Rev Clin Oncol 2017; 14: 73–74. doi:10.1038/nrclinonc.2016.221

    Author:
    Prashant Kapoor, S. Vincent Rajkumar
  4. 04-01-2016 | Treatment | Article

    Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity

    Ixazomib has demonstrated enhanced proteasomal inhibition. 98 In a phase II trial evaluating single-agent ixazomib in patients with relapsed MM, the ORR was 34%.

    Author:
    R F Cornell, A A Kassim
  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.